As economies all around the world are suffering from the impact of Covid-19, businesses are experiencing losses, workers are without jobs, and many face the challenge of a complete upheaval of lifestyle. However, pharmaceutical companies taking centre stage in the Covid-19 fight and a new innovation in the infectious disease landscape as the race for treatment approval for a Covid-19 therapy takes off.
Pharmaceutical companies are on the line and their impact on the fight against the virus will not be easily forgotten. The concept of large profits coming from newly developed drugs will increased consider in a time of global pandemic as a result of public and competitive pressures.
Title : Macitentan/Tadalafil Combination– An additional value in pharmacotherapy of pulmonary arterial hypertension
Miroslav Radenkovic, University of Belgrade, Serbia
Title : Navigating the regulatory landscape for nanotechnology-based pharmaceuticals: challenges and strategies for harmonization
Srividya Narayanan, Northeastern University, United States
Title : Metformin-loaded nanoparticles reduce hyperglycemia-associated oxidative stress and induce enos phosphorylation in vascular endothelial cells
Haitham A Saleh, Qatar University, Qatar
Title : Proposomes as a promising approach for topical application of Allantoin intended against ultraviolet induced photoaging
Eman Shalaby, National Research Centre, Egypt
Title : Trends in antimicrobial resistance in Gaza Strip, 2020-2022
Hashem M Mansour, Indonesian Hospital, State of Palestine
Title : Medical liver Biopsy: Toward a personalized approach
Consolato M Sergi, Universities of Alberta and Ottawa, Canada
Title : Drug development - Importance, trends and digital transformation
Gurpreet Singh, IQVIA, United Kingdom